source
- Moderna and Merck's mRNA melanoma vaccine cuts recurrence risk by 42% in trialA large Phase 2 trial led by Moderna and Merck showed that their personalized mRNA vaccine, intismeran autogene, lowered the chance of melanoma returning by 42% compared with standard therapy. The…
- FDA issues final guidance on drug-related mobile applicationsThe FDA has released its final guidance addressing software applications that are used in connection with prescription drugs. The guidance clarifies how the agency will evaluate and regulate apps…